I want to take a moment to explain something that is easy to underestimate from the outside: how difficult this discovery actually was, and why it took the path—and the time—that it did.

This did not begin as a product idea. It began as a scientific problem.

The fulcrum was nicotinic acid—immediate-release, unambiguous, mechanistically clean. That was the anchor. My own doctoral work already pointed there: NAD⁺ depletion is real, consequential, and upstream. Starting with nicotinic acid was not arbitrary; it was the most direct way to restore NAD⁺ without forcing the body to cannibalize its own protein-bound tryptophan.

But very early on, I also knew something was incomplete.

Niacin works—no question—but it plateaus. It can only do so much. If NAD⁺ restoration were the entire story, more people would fully recover. They don’t. That discrepancy mattered to me, because it meant the biology wasn’t finished revealing itself yet.

What followed was not a straight line. It was years of testing, discarding, recalibrating, and refusing to stop just because partial benefit looked “good enough.”

Eventually, the missing variable became clear: tryptophan.

Even that realization did not solve the problem.

Identifying tryptophan is one thing. Understanding how tightly it is coupled to nicotinic acid biology is another entirely. These are not independent nutrients. They are linked through NAD⁺ demand, protein preservation, cortisol signaling, and the kynurenine pathway. You cannot simply “add tryptophan” and expect improvement.

In fact, getting the ratio wrong, in this case, could have made recovery never come in time.

Too much tryptophan pushes excess flux down the kynurenine pathway. Too little fails to restore what was chronically lost while NAD⁺ demand was unmet. Either error can mask the underlying signal and make the entire approach appear wrong—when in reality it is imprecise.

That precision took time.

There were periods where doubling, tripling, or quadrupling tryptophan relative to nicotinic acid looked promising on the surface—but biologically, it wasn’t correct. The potency of tryptophan means excess is not benign. Efficiency matters. Directionality matters. Waste matters.

At the same time, I deliberately resisted the temptation to stop at “niacin alone,” even though I could have. I knew the puzzle was incomplete, and I also knew that if I didn’t finish it, most people would never fully get better—only partially improved.

That mattered more to me than speed.

Along the way, we trimmed what wasn’t necessary. Vitamin C had a role early on, but once the coupling became clear, it no longer belonged in the core formulation. Removing things is often harder than adding them—but clarity requires subtraction.

What finally emerged was not just the identification of two nutrients, but a pinpoint-precise alignment between them. A ratio that restores lost tryptophan without driving excess kynurenine activity. A configuration that complements nicotinic acid instead of competing with it. A system that reflects how human biology actually works—not how supplements are usually assembled.

This is why earlier versions were close—but not complete.

And this is why this version is different.

I genuinely appreciate those of you who stayed with me through this process—not just for yourselves, but because real discovery requires patience. What looks obvious in hindsight rarely is while you’re in it.

This was not about selling something quickly. It was about finishing the science correctly.

And now, for the first time, I can say with confidence: this is right.

Thank you for trusting the process.